{"id":130472,"date":"2022-06-06T04:43:28","date_gmt":"2022-06-06T08:43:28","guid":{"rendered":"https:\/\/44.250.171.167\/?p=130472"},"modified":"2022-10-06T04:26:55","modified_gmt":"2022-10-06T08:26:55","slug":"hikal-limited-q4-fy22-earnings-conference-call-insights","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/hikal-limited-q4-fy22-earnings-conference-call-insights\/","title":{"rendered":"Hikal Limited Q4 FY22 Earnings Conference Call Insights"},"content":{"rendered":"<p><iframe loading=\"lazy\" title=\"Hikal Limited Q4 FY22 Earnings Concall\" width=\"500\" height=\"375\" src=\"https:\/\/www.youtube.com\/embed\/3z2q_SR1OS4?feature=oembed\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe><\/p>\n<p><strong>Key highlights from Hikal Limited (<a href=\"https:\/\/44.250.171.167\/symbol\/HIKAL\/\">HIKAL<\/a>) Q4 FY22 Earnings Concall<\/strong><\/p>\n<p><strong>Management Update:<\/strong><\/p>\n<ul>\n<li>HIKAL said its new product launches in anti-diabetic have been witnessing increased traction from customers. The company has 10 plus products in development pipeline and are planning to launch 4-5 products in FY23.<\/li>\n<\/ul>\n<ul>\n<li>HIKAL is planning to complete the plant commissioning of its new fungicide by end of 3Q23, and start revenue generation by end of FY23. HIKAL is also planning to launch one more fungicide with the combined potential of INR400-500 crore.<\/li>\n<\/ul>\n<p><strong>Q&amp;A Highlights:<\/strong><\/p>\n<ul>\n<li>Rahul Jain of Credence Wealth asked that on the growth, demand and the sales revenue path, what has changed in the last 2-3 months, where the commentary has changed from being buoyant to a cautious outlook. Vimal Kulshrestha President said the demand is strong. The challenge has been of supply chain in 4Q22. HIKAL is expecting a lag in passing the cost impact, but is confident of passing on this impact from 2Q23.<\/li>\n<\/ul>\n<ul>\n<li>Rahul Jain of Credence Wealth also asked that on the pharma and agro side margins were below avg. for last three quarters and if it\u2019s expected to be same going forward. Anish Swadi BD said it\u2019s difficult for HIKAL to give guidance in terms of margin right now as things are uncertain and fluid. HIKAL said 1Q23 will certainly be more subdued than 4Q22. But 2Q23 onwards, there will be an improvement going forward.<\/li>\n<\/ul>\n<ul>\n<li>Rahul Jain of Credence Wealth asked that on the growth path if the company is more confident on the topline vs. the margin. Anish Swadi BD said it\u2019s difficult for HIKAL to give revenue and margin guidance. The company is hopeful that end of 2Q22 onwards HIKAL will see a resurrection in terms of the business.<\/li>\n<\/ul>\n<ul>\n<li>Rahul Jain of Credence Wealth enquired that what amount of capex capitalization does HIKAL expect in FY23. Kuldeep Jain CFO replied that the company is expecting INR250-275 crore cash flow in FY22 and the capitalization will be close to INR400 crore.<\/li>\n<\/ul>\n<ul>\n<li>Rahul Jain of Credence Wealth also asked about the capex schedule in terms of the commercials being started in FY23. Kuldeep Jain CFO replied that for crop capex, HIKAL expects to commission in 3Q23 and revenue addition from 4Q23.<\/li>\n<\/ul>\n<ul>\n<li>Ankit Gupta from Bamboo Capital asked if HIKAL\u2019s 1-1.5% margin improvement on a base of 19-20% guidance can be seen from FY24 every year. Kuldeep Jain CFO said that the company should be able to see that improvement and HIKAL is working towards that.<\/li>\n<\/ul>\n<ul>\n<li>Ankit Gupta from Bamboo Capital also enquired that on the capex side, given the headwinds faced currently, what\u2019s the capex plan for FY23 and FY24. Anish Swadi BD answered that currently for FY24, HIKAL doesn\u2019t have any capex as it all depends on where the company is today. So the capex commitment that\u2019s good to have is at this point in time deferring probably till 2H23.<\/li>\n<\/ul>\n<ul>\n<li>Ankit Gupta from Bamboo Capital enquired about the capex committmet for FY23 from customers. \u00a0Anish Swadi BD replied that it will be in the range of INR250-270 crores.<\/li>\n<\/ul>\n<ul>\n<li>Ankit Gupta from Bamboo Capital asked about the reason of slow growth in Pharma side and how much growth is expected in the segment during FY24 and FY25. Manoj Mehrotra President said HIKAL is expecting to launch more new products on the API side and building new relationships on the CDMO side. HIKAL expects the growth to be in the range of close to 12-15% going forward.<\/li>\n<\/ul>\n<ul>\n<li>Dhwanil Desai from Turtle Capital asked about the animal health contract, capex incurred and revenue potential over next three years. Anish Swadi BD said since it\u2019s a confidential contract, HIKAL is not disclosing the amount of investment. However, HIKAL\u2019s customer is contributing to 50% of capex. The revenue is going to be more or less in line of what the company is doing today, which is 1.5 times the asset HIKAL is putting in.<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Key highlights from Hikal Limited (HIKAL) Q4 FY22 Earnings Concall Management Update: HIKAL said its new product launches in anti-diabetic have been witnessing increased traction from customers. The company has 10 plus products in development pipeline and are planning to launch 4-5 products in FY23. HIKAL is planning to complete the plant commissioning of its [&hellip;]<\/p>\n","protected":false},"author":1767,"featured_media":125416,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[9825,392,5747],"tags":[1115],"class_list":["post-130472","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-earnings-call-highlights","category-earnings","category-healthcare-stocks","tag-pharmaceuticals"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":127925,"url":"https:\/\/alphastreet.com\/india\/hikal-limited-q3-fy22-earnings-conference-call-insights\/","url_meta":{"origin":130472,"position":0},"title":"Hikal Limited Q3 FY22 Earnings Conference Call Insights","author":"Praveen","date":"February 24, 2022","format":false,"excerpt":"Key highlights from Hikal Limited (HIKAL) Q3 FY22 Earnings Concall Management Update: HIKAL stated that the company expects some short term impact on the operations of Crop Protection business due to the recent receipt of a MPCB notice. Q&A Highlights: Rahul Jain from Credence Wealth asked about the pharma business\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":147524,"url":"https:\/\/alphastreet.com\/india\/earnings-summary-of-hikal-limited-for-q4-fy23\/","url_meta":{"origin":130472,"position":1},"title":"Earnings Summary Of Hikal Limited For Q4 FY23","author":"Hardik Bhandare","date":"May 30, 2023","format":false,"excerpt":"Hikal Limited is a leading global chemical company based in India. With over three decades of experience, the company specializes in the manufacturing and development of advanced chemicals, pharmaceutical intermediates, and crop protection products. Hikal operates across various industry segments, including agrochemicals, pharmaceuticals, and specialty chemicals. The company has a\u2026","rel":"","context":"In &quot;Earnings&quot;","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-7-5.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-7-5.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-7-5.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-7-5.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-7-5.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-7-5.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":142188,"url":"https:\/\/alphastreet.com\/india\/earnings-summary-of-hikal-limited-for-q3-fy23\/","url_meta":{"origin":130472,"position":2},"title":"Earnings Summary Of Hikal Limited For Q3 FY23","author":"Hardik Bhandare","date":"February 17, 2023","format":false,"excerpt":"Hikal Limited (NSE: HIKAL) is a leading Indian life sciences company with a global presence. The company specializes in developing and manufacturing intermediates, active pharmaceutical ingredients (APIs), and specialty chemicals for the pharmaceutical, agrochemical, and animal health industries. HIKAL has a strong focus on innovation and quality, which has helped\u2026","rel":"","context":"In &quot;Earnings&quot;","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-1-3.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-1-3.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-1-3.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-1-3.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-1-3.jpg?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-1-3.jpg?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":151879,"url":"https:\/\/alphastreet.com\/india\/hikal-ltd-q1fy24-2-rise-in-revenue\/","url_meta":{"origin":130472,"position":3},"title":"Hikal Ltd Q1FY24; 2% rise in Revenue","author":"Hardik Bhandare","date":"August 8, 2023","format":false,"excerpt":"Hikal is a partner to companies in the Pharmaceuticals, Crop Protection, and Specialty Chemicals industry. The company is in the business of supplying research services, active ingredients and intermediates for its customers. Hikal's manufacturing facilities have been inspected and approved by leading multinational companies in the Crop protection and Pharmaceutical\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-403.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-403.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-403.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-403.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-403.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-403.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":156376,"url":"https:\/\/alphastreet.com\/india\/hikal-ltd-q2fy24-48-fall-in-profits\/","url_meta":{"origin":130472,"position":4},"title":"Hikal Ltd Q2FY24; 48% fall in Profits","author":"Hardik Bhandare","date":"November 17, 2023","format":false,"excerpt":"Hikal is a partner to companies in the Pharmaceuticals, Crop Protection, and Specialty Chemicals industry. The company is in the business of supplying research services, active ingredients and intermediates for its customers. Hikal's manufacturing facilities have been inspected and approved by leading multinational companies in the Crop protection and Pharmaceutical\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/11\/image-233.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/11\/image-233.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/11\/image-233.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/11\/image-233.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/11\/image-233.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/11\/image-233.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":162724,"url":"https:\/\/alphastreet.com\/india\/hikal-ltd-q4fy24-6-fall-in-profits\/","url_meta":{"origin":130472,"position":5},"title":"Hikal Ltd Q4FY24; 6% fall in Profits","author":"Divyansh_Kasana","date":"July 3, 2024","format":false,"excerpt":"Hikal is a partner to companies in the Pharmaceuticals, Crop Protection, and Specialty Chemicals industry. The company is in the business of supplying research services, active ingredients and intermediates for its customers. Hikal's manufacturing facilities have been inspected and approved by leading multinational companies in the Crop protection and Pharmaceutical\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/07\/image-31.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/07\/image-31.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/07\/image-31.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/07\/image-31.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/07\/image-31.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/07\/image-31.png?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/130472","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1767"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=130472"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/130472\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/125416"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=130472"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=130472"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=130472"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}